The 2021 Cancer R&D Spotlight

Every year the biopharma industry turns to ASCO to help define where cancer drug R&D is headed. Endpoints News will bring together a group of experts to discuss the most important presentations at the conference, with insights on the winners and losers at ASCO 21.

After CD19, BCMA became the cancer target that everyone wanted to hit. And even with a couple of approvals here, there’s a slew of rivals looking to come out on top. Endpoints Editor John Carroll will examine 4 of the leading programs in a look at the latest cutting edge drugs being tested in the clinic.

Theranostics, the use of radiolabeled targeted compounds, combines diagnostic imaging with targeted therapy. The acquisition of Endocyte and AAA by Novartis and the recent positive phase 3 results with 177Lu-PSMA-617 have helped a once unfamiliar field become more attractive and accessible.

In this roundtable discussion, the panelists will review the unique challenges and requirements involved with the non-clinical and clinical development of Theranostics, including:

• Discussing the different targeting platforms and strategies used to develop new Theranostic agents.
• Reviewing the potential of combination therapies that utilize the mechanism of action alpha- and beta-emitting radiation.
• Addressing normal organ radiation dose limits, the use of dosimetry and biomarkers to monitor kidney/marrow damage and whether current radiation limits require updating.